Skip to main content
Clinical Trials/NCT03806582
NCT03806582
Completed
Phase 4

Effect of a Higher Blood-pressure on Right Ventricular Function

Medical Centre Leeuwarden1 site in 1 country78 target enrollmentMarch 1, 2019

Overview

Phase
Phase 4
Intervention
Norepinephrine
Conditions
Blood Pressure
Sponsor
Medical Centre Leeuwarden
Enrollment
78
Locations
1
Primary Endpoint
right ventricular ejection fraction
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Right ventricular (RV) dysfunction in cardiac surgery is an independent risk factor for morbidity and mortality. Raising the systemic blood pressure with norepinephrine seems to have a positive influence on the right ventricular function in several animal studies. The current study is designed to evaluate the effect of a higher blood pressure on the RV function in post cardiac surgery patients.

Detailed Description

Goal: To demonstrate differences in RV function by raising the systemic blood pressure with norepinephrine. Study design: randomized controlled trial Study population: 78 postoperative cardiac surgery patients admitted at the ICU. Intervention: * Group 1: (N=22): RVEF\<20% and MAP≤65mmHg. Intervention with norepinephrine to reach a MAP of 85mmHg for a maximum duration of two hours. * Group 2: (N=22): RVEF \<20% and MAP≤65mmHg. Control group: treatment according to current standards. Hypotensive patients are treated with fluids and/or vasopressors to gain a mean arterial pressure (MAP) of 65mmHg. * Group 3: (N=17): RVEF between ≥20 and \<30% and MAP ≤65mmHg. Intervention with norepinephrine to reach a MAP of 85mmHg for a maximum duration of two hours. * Group 4: (N=17): RVEF between ≥20 and \<30% and MAP ≤65mmHg. Control group: treatment according to current standards. Hypotensive patients are treated with fluids and/or vasopressors to gain a mean arterial pressure (MAP) of 65mmHg. Endpoints: Primary endpoint is the difference between the intervention and the control group in the change over time between baseline and the end of the study period (T4) in RVEF. Secondary endpoints are the echocardiographic parameters of RV and LV contractility, RV end-diastolic pressure, cardiac index, and fluid balance.

Registry
clinicaltrials.gov
Start Date
March 1, 2019
End Date
May 25, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Medical Centre Leeuwarden
Responsible Party
Principal Investigator
Principal Investigator

E.C. Boerma

Dr

Medical Centre Leeuwarden

Eligibility Criteria

Inclusion Criteria

  • post operative cardiac surgery patients, full sternotomy
  • admission at ICU
  • informed consent
  • right ventricular monitoring by pulmonary artery catheter.
  • RVEF \<30% + MAP ≤ 65mmHg

Exclusion Criteria

  • no informed consent
  • acute surgery
  • Off pump cardiac surgery
  • Severe tricuspid insufficiency
  • Allergy to norepinephrine
  • Severe left ventricular hypertrophy with systolic anterior movement
  • Chronic use of alpha-blockers
  • Irregulair heart rhythm
  • Surgical reasons to maintain a low blood pressure.

Arms & Interventions

intervention

intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function

Intervention: Norepinephrine

Outcomes

Primary Outcomes

right ventricular ejection fraction

Time Frame: 2 hours postoperative

Primary endpoint is the difference between the intervention and the control group in the change over time between baseline and the end of the study period (T4) in RVEF.

Secondary Outcomes

  • Echocardiographic(2 hours postoperative)
  • RV end-diastolic pressure(baseline and 15 minutes postoperatively)
  • Cardiac index(2 hours postoperative)
  • Fluid balance(2 hours postoperative)

Study Sites (1)

Loading locations...

Similar Trials